Is It Too Late To Consider Insmed (INSM) After A 109% One Year Surge?

Simply Wall St.

Apr 16

If you are wondering whether Insmed at around US$146.74 still offers value after a strong run in the share price, the key is to look closely at what different valuation methods are saying today. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2627129587"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627129587\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627129587?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-16 16:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627129587","market":"nz","top_or_hot":-1,"title":"Is It Too Late To Consider Insmed (INSM) After A 109% One Year Surge?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Insmed at around US$146.74 still offers value after a strong run in the share price, the key is to look closely at what different valuation methods are saying today. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/is-it-too-late-to-consider-insmed-insm-after-a-109-one-year\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late To Consider Insmed (INSM) After A 109% One Year Surge?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late To Consider Insmed (INSM) After A 109% One Year Surge?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-16 16:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/is-it-too-late-to-consider-insmed-insm-after-a-109-one-year><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Insmed at around US$146.74 still offers value after a strong run in the share price, the key is to look closely at what different valuation methods are saying today. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/is-it-too-late-to-consider-insmed-insm-after-a-109-one-year\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0889565916.HKD","symbol_name":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/is-it-too-late-to-consider-insmed-insm-after-a-109-one-year","article_id":"2627129587","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/is-it-too-late-to-consider-insmed-insm-after-a-109-one-year","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627129587","pubTimestamp":1776327016,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Insmed at around US$146.74 still offers value after a strong run in the share price, the key is to look closely at what different valuation methods are saying today.\nThe stock has been volatile, with a 1 year return of 109.0%, a very large 3 year gain, and a 7 day return of an 8.4% decline, which can change how the market prices both its potential and its risks.\nRecent coverage has focused on Insmed's position in biotech, its late stage pipeline assets, and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","INSM":"Insmed","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","FCF":"第一联邦金融","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4211":"区域性银行"},"translate_title":"在一年飙升109%之后，现在考虑Insmed(INSM)是否为时已晚？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1.5,"DCF":1,"FCF":1},"content_text":"If you are wondering whether Insmed at around US$146.74 still offers value after a strong run in the share price, the key is to look closely at what different valuation methods are saying today. The stock has been volatile, with a 1 year return of 109.0%, a very large 3 year gain, and a 7 day return of an 8.4% decline, which can change how the market prices both its potential and its risks. Recent coverage has focused on Insmed's position in biotech, its late stage pipeline assets, and ongoing development programs. All of these factors can influence how investors frame its long term prospects. At the same time, broader discussion around higher risk growth names has kept attention on companies like Insmed when sentiment shifts. Right now, Insmed scores a 3 out of 6 valuation checks, so the next step is to break down what different valuation approaches say about that score and then finish with a way to judge value that ties the numbers back to the full investment story.  Insmed delivered 109.0% returns over the last year. See how this stacks up to the rest of the Biotechs industry. AdvertisementApproach 1: Insmed Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and then discounting those back to a present value using a required rate of return. For Insmed, the model used is a 2 Stage Free Cash Flow to Equity approach. The last twelve months free cash flow (FCF) is a loss of $967.24 million. Analyst estimates and extrapolations point to FCF moving from a projected loss of $589.95 million in 2026 to positive figures such as $797.57 million in 2028 and $2,386.63 million in 2030, all in US$. Simply Wall St discounts these projected cash flows, along with further extrapolated figures out to 2035, to reach an estimated intrinsic value of about $367.66 per share. Compared with the current share price of roughly $146.74, this output implies Insmed is 60.1% undervalued on this model. This DCF view suggests the market price is well below what these long term cash flow projections would support. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Insmed is undervalued by 60.1%. Track this in your watchlist or portfolio, or discover 60 more high quality undervalued stocks. INSM Discounted Cash Flow as at Apr 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Insmed. Approach 2: Insmed Price vs Book For companies where earnings or cash flows are not yet a steady guide, investors often look at price relative to book value, or P/B, as a cross check on how much they are paying for the net assets that support the business. In practice, the P/B multiple a stock trades on tends to reflect what the market thinks about its growth potential and risk. Higher growth expectations or lower perceived risk can support a higher “normal” P/B, while slower expected growth or higher risk usually points to a lower one. Insmed currently trades on a P/B of 42.86x. This sits well above the Biotechs industry average of about 2.37x and the peer group average of 21.22x. Simply Wall St also uses a “Fair Ratio” framework for P/B, which estimates the multiple that might be appropriate after considering factors like earnings growth, profit margins, market cap, risks and the company’s industry. That makes it a more tailored reference point than simple comparisons with peers or the sector. On this measure, Insmed’s current 42.86x P/B is far above the Fair Ratio benchmark, which points to the shares being expensive on a book value basis. Result: OVERVALUED NasdaqGS:INSM P/B Ratio as at Apr 2026 P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies. Upgrade Your Decision Making: Choose your Insmed Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives are a simple way for you to write the story behind your numbers by linking your view of Insmed’s products, launches and risks to a financial forecast for future revenue, earnings and margins. This then flows through to a fair value that you can compare with the current share price inside the Simply Wall St Community page. Narratives are updated as new news or earnings arrive, and different investors can sit anywhere between the most bullish analyst view with a US$245.00 fair value and the most cautious at US$177.00, depending on which assumptions they find more realistic. Do you think there's more to the story for Insmed? Head over to our Community to see what others are saying! NasdaqGS:INSM 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}